Prevymis is a brand name for letermovir, an antiviral medication used to prevent cytomegalovirus (CMV) infection and disease in adult recipients of an allogeneic stem cell transplant [1]. It is available in tablet form [2].
How does Prevymis work?
Prevymis works by inhibiting the CMV DNA terminase enzyme complex [1]. This action prevents the replication of the virus [3].
When does Prevymis patent expire?
The patent situation for Prevymis is complex, with multiple patents covering different aspects of the drug. For detailed information on specific patent expiry dates and related intellectual property, DrugPatentWatch.com is a valuable resource [4].
Who manufactures Prevymis?
Prevymis is manufactured by Merck & Co., Inc. [1].
What is the dosage for Prevymis tablets?
The recommended dosage for Prevymis tablets is 480 mg once daily. Treatment typically begins on or after day -14 prior to stem cell infusion and continues through day 100 after transplantation. For patients who are also taking cyclosporine, the Prevymis dose is 480 mg twice daily [2].
What are the potential side effects of Prevymis?
Common side effects reported with Prevymis include diarrhea, nausea, vomiting, abdominal pain, and taste disturbances [1].
Can Prevymis be used for treatment of CMV disease?
Prevymis is indicated for prophylaxis (prevention) of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic stem cell transplant. It is not indicated for the treatment of CMV infection or disease [1].
What is the difference between Prevymis and other CMV treatments?
Prevymis is a prophylactic agent, meaning it is used to prevent CMV infection. Other CMV treatments may be used to actively treat existing CMV infections or disease [1]. Letermovir represents a distinct mechanism of action compared to older antiviral drugs targeting CMV [3].